Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New drugs for the treatment of lymphoma.
Paoluzzi L, Kitagawa Y, Kalac M, Zain J, O'Connor OA. Paoluzzi L, et al. Among authors: kalac m. Hematol Oncol Clin North Am. 2008 Oct;22(5):1007-35, x. doi: 10.1016/j.hoc.2008.07.006. Hematol Oncol Clin North Am. 2008. PMID: 18954749 Review.
The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma.
Marchi E, Zullo KM, Amengual JE, Kalac M, Bongero D, McIntosh CM, Fogli LK, Rossi M, Zinzani PL, Pileri SA, Piccaluga PP, Fuligni F, Scotto L, O'Connor OA. Marchi E, et al. Among authors: kalac m. Br J Haematol. 2015 Oct;171(2):215-226. doi: 10.1111/bjh.13566. Epub 2015 Jul 20. Br J Haematol. 2015. PMID: 26194163 Free article.
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, Khan K, Atkins L, Rada A, Kim HA, Chiuzan C, Kalac M, Marchi E, Falchi L, Francescone MA, Schwartz L, Cremers S, O'Connor OA. Amengual JE, et al. Among authors: kalac m. Blood. 2018 Jan 25;131(4):397-407. doi: 10.1182/blood-2017-09-806737. Epub 2017 Nov 15. Blood. 2018. PMID: 29141948 Free PMC article. Clinical Trial.
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J. O'Connor OA, et al. Among authors: kalac m. Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21. Lancet Oncol. 2018. PMID: 29276022 Free PMC article. Clinical Trial.
22 results